Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea · Delayed Price · Currency is KRW 472,000
-2,000 (-0.42%)
Last updated: Nov 18, 2025, 10:48 AM KST
Hanmi Pharm. Revenue
Hanmi Pharm. had revenue of -389.93B KRW in the quarter ending September 30, 2025, a decrease of -207.69%. This brings the company's revenue in the last twelve months to 1.50T, down -4.50% year-over-year. In the year 2024, Hanmi Pharm. had annual revenue of 1.50T with 0.31% growth.
Revenue (ttm)
1.50T
Revenue Growth
-4.50%
P/S Ratio
3.91
Revenue / Employee
623.21M
Employees
2,400
Market Cap
5.85T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.50T | 4.61B | 0.31% |
| Dec 31, 2023 | 1.49T | 159.34B | 11.97% |
| Dec 31, 2022 | 1.33T | 128.36B | 10.67% |
| Dec 31, 2021 | 1.20T | 127.33B | 11.84% |
| Dec 31, 2020 | 1.08T | -37.80B | -3.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |